Affimed does deal with Janssen, as subsidiary secures funding

15 July 2013

German’s privately-owned biopharmaceutical company Affimed Therapeutics has entered into an agreement with Janssen Biotech, a unit of US health care giant Johnson & Johnson (NYSE: JNJ), that grants Janssen the exclusive right to acquire Affimed’s subsidiary Amphivena Therapeutics, following grant of Investigational New Drug status for its lead product candidate on pre-negotiated terms and conditions set forth in the accord.

Janssen will provide Amphivena with an initial upfront payment plus additional contingent payments based on reaching predetermined milestones in return for its rights under the agreement. Further financial terms were not disclosed.

Affimed AG, the therapeutic TandAb antibody company has entered into a license and development agreement with Amphivena to support the discovery and preclinical development of the novel TandAb based therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK